Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Trial of MK-3475 (Pembrolizumab) and Interferon Gamma 1-b Combination Immunotherapy in Patients With Previously Treated Mycosis Fungoides and Sezary Syndrome (Treatment Group 1) and in Patients With Advanced Synovial Sarcoma (Treatment Group 2)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03063632
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:30.735392+00:00
Published At
2022-08-30T00:00:00+00:00
Record Updated At
2023-10-25
Results Posted At
2022-08-30
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Metastatic Myxoid Liposarcoma", "Metastatic Round Cell Liposarcoma", "Metastatic Synovial Sarcoma", "Recurrent Mycosis Fungoides and Sezary Syndrome", "Refractory Mycosis Fungoides and Sezary Syndrome", "Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7", "Unresectable Synovial Sarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-10-25"
protocolSection.identificationModule.nctId
"NCT03063632"
protocolSection.identificationModule.officialTitle
"A Phase II Trial of MK-3475 (Pembrolizumab) and Interferon Gamma 1-b Combination Immunotherapy in Patients With Previously Treated Mycosis Fungoides and Sezary Syndrome (Treatment Group 1) and in Patients With Advanced Synovial Sarcoma (Treatment Group 2)"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2022-08-30"

Study condition terms

  • Metastatic Myxoid Liposarcoma (protocolSection.conditionsModule.conditions)
  • Metastatic Round Cell Liposarcoma (protocolSection.conditionsModule.conditions)
  • Metastatic Synovial Sarcoma (protocolSection.conditionsModule.conditions)
  • Recurrent Mycosis Fungoides and Sezary Syndrome (protocolSection.conditionsModule.conditions)
  • Refractory Mycosis Fungoides and Sezary Syndrome (protocolSection.conditionsModule.conditions)
  • Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7 (protocolSection.conditionsModule.conditions)
  • Unresectable Synovial Sarcoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.